DivestmentJul 28, 2026, 08:02 AM
Standard BioTools Sells Mass Cytometry Business; Gets $30M Illumina Buyout
AI Summary
Standard BioTools announced the sale of its Mass Cytometry business to Multiplex Bio for up to $10 million, ensuring continuity of CyTOF and Hyperion product lines. Concurrently, the company received approximately $30 million from Illumina as a buyout for the 2026 earnout and future royalty payments related to the SomaLogic business acquisition. Additionally, the U.S. Federal Trade Commission granted early termination of the waiting period for Standard BioTools' merger with Treeline Biosciences, which is expected to close by year-end 2026, subject to stockholder approval.
Key Highlights
- Sold Mass Cytometry business to Multiplex Bio for up to $10 million.
- Received approximately $30 million from Illumina for SomaLogic earnout and royalties.
- Provided Multiplex Bio with a working capital loan of up to $10 million.
- Mass Cytometry business sale expected to close by end of 2026.
- Early termination of HSR waiting period for Treeline merger.
- Treeline merger expected to close by end of 2026, subject to stockholder approval.
Price Impact
More from LAB